Placental growth factor at 24–28 weeks for aspirin discontinuation in pregnancies at high risk for preterm preeclampsia: Post hoc analysis of <scp>StopPRE</scp> trial

Discontinuation of aspirin treatment at 24-28 weeks in women with PlGF levels ≥100 pg/mL was non-inferior to continuing until 36 weeks for preventing preterm PE. However, these findings should be interpreted with caution, as they originate from a subanalysis of the StopPRE trial.

Authors

Institutions

Publication Details

Journal
Acta Obstetricia Et Gynecologica Scandinavica
Published
2024-08-22
DOI
https://doi.org/10.1111/aogs.14955
Citations
4
Primary Topic
Pregnancy and preeclampsia studies
Type
article
Field-Weighted Citation Impact
2.33

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Placental growth factor at 24–28 weeks for aspirin discontinuation in pregnancies at high risk for preterm preeclampsia: Post hoc analysis of StopPRE trial

Carmen Lago, Sara Caamiña, Pablo García‐Manau, Anna Suy et al.
4 citations
Acta Obstetricia Et Gynecologica Scandinavica
Pregnancy and preeclampsia studies
2.33
article

Placental growth factor at 24–28 weeks for aspirin discontinuation in pregnancies at high risk for preterm preeclampsia: Post hoc analysis of StopPRE trial

Carmen Lago, Sara Caamiña, Pablo García‐Manau, Anna Suy, Esperanza Garcı́a, Mar Pallarols, M. Ricart, Mireia Teixidor, Elena Pintado, Laura de Mingo, Anna Maroto, Alicia Rodríguez-Zurita, Eva López‐Quesada, E. Carreras, Laia Pratcorona, Erika Bonacina, Roser Ferrer, Vanesa Ocaña, Àngels Vives, Lourdes Martín, Manel Mendoza, Monica López, Ester del Barco
article en
4 citations

Abstract

Discontinuation of aspirin treatment at 24-28 weeks in women with PlGF levels ≥100 pg/mL was non-inferior to continuing until 36 weeks for preventing preterm PE. However, these findings should be interpreted with caution, as they originate from a subanalysis of the StopPRE trial.

Acta Obstetricia Et Gynecologica ScandinavicaVol. 103(11)
Universitat Autònoma de Barcelona (ES), Hospital Universitario Nuestra Señora de Candelaria (ES), Consorci Sanitari de Terrassa (ES), Hospital Universitario de Getafe (ES), Vall d'Hebron Hospital Universitari (ES), Mútua Terrassa (ES), Hospital Universitari Joan XXIII de Tarragona (ES), Hospital Universitari Germans Trias i Pujol (ES), Hospital Universitari de Girona Doctor Josep Trueta (ES), Hospital Universitario Severo Ochoa (ES)
Ministerio de Asuntos Económicos y Transformación Digital, Gobierno de España
Good health and well-being
Openalex Percentile: Top 12%
Pregnancy and preeclampsia studies
2.33
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.